{"id":7996,"date":"2026-06-16T09:07:27","date_gmt":"2026-06-16T16:07:27","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7996"},"modified":"2026-07-16T09:09:29","modified_gmt":"2026-07-16T16:09:29","slug":"highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","title":{"rendered":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

16 6 \u6708, 2026 | HighField Bio Press Release<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

HighField Biopharmaceuticals Launches\nPhase 2 Trial of K16, a First-in-Class Lipid-Based Drug\nfor Recurrent and Progressive Brain Cancer\n<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0<\/strong><\/em><\/p>

The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive brain cancer.<\/strong><\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/p>

HANGZHOU, CHINA, (June 16, 2026)<\/strong> \u2013 HighField Biopharmaceuticals, a clinical stage company using new, more effective lipid-based therapeutics to treat cancer and other diseases, announced today it has launched a Phase 2 trial of K16 in combination with bevacizumab for recurrent or progressive glioma in China.<\/p>

HighField CEO Yuhong Xu, Ph.D., explained K16\u2019s liposomal construct of ATRA targets myeloid-derived suppressor cells (MDSC) that play a key role in the immune suppressing tumor microenvironment. K16 is the first drug to modulate myeloid cells and promote maturation and differentiation of MDSCs into functional immune cells that attack cancer.<\/p>

Dr. Xu said, \u201cOur Phase 1 trial of K16 as a single agent suggested significant efficacy for treatment of recurrent glioma. In the Phase 2 trial, we are combining K16 with bevacizumab to provide a first-of-its-kind knock-out blow to brain cancer.\u201d<\/p>

In the Phase 1 trial of K16 for glioma the overall median survival of 17 patients was more than 18 months. One patient experienced a complete response and remains cancer free after four years. Typically, for patients with glioblastoma, the most aggressive form of glioma, the one-year survival rate is about 25% to 40%.<\/p>

In addition to the open-label multicenter Phase 2 trial for glioma (NCT07678684<\/a>), HighField plans to initiate additional clinicals trials of K16 for other solid tumors.<\/p>

A Unique Lipid Technology
<\/strong>HighField is the first to develop lipid structures that can navigate complex biological systems such as the tumor microenvironment and the immune system for novel treatments of cancer, autoimmune, metabolic and other diseases. The products are high-quality lipid nanoparticles designed with a unique modular system to be biocompatible as they travel in circulation and highly efficient in finding diseased tissues. These nanoparticles, optimized for targeting multiple disease mechanisms and cells, can safely carry various payloads in specific quantities for maximum efficacy.<\/p>

\u5173\u4e8e HighField \u751f\u7269\u5236\u836f
<\/strong>Highfield is a clinical stage company focused on novel applications of liposome constructs directed to immuno-oncology and gene therapy. \u00a0HighField\u2019s lead products target various cancers. K16 is a liposomal construct of all-trans retinoic acid (ATRA) in combination with bevacizumab. \u00a0K1 is a drug encapsulated immunoliposome derived from HighField\u2019s ADCplex\u5546\u6807<\/sup> platform and HF50 is derived from the company\u2019s TCEplex\u5546\u6807 <\/sup>T cell engager platform. For more information visit https:\/\/highfieldbio.com\/<\/a>.<\/p>

\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a<\/strong>
\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89
Opus \u751f\u7269\u6280\u672f\u901a\u8baf
danieleramian@comcast.net<\/a>
425-306-8716<\/p>

\u4e1a\u52a1\u53d1\u5c55\u8054\u7cfb\u4eba\uff1a<\/strong>
\u6c5f\u94f6
Highfield Biopharmaceuticals Inc
Jiangxy@hf-biopharm.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]<\/p>","protected":false},"author":1,"featured_media":7606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"\nHighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T16:07:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T16:09:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PJWCreative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"},\"author\":{\"name\":\"PJWCreative\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\"},\"headline\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer\",\"datePublished\":\"2026-06-16T16:07:27+00:00\",\"dateModified\":\"2026-07-16T16:09:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"},\"wordCount\":461,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\",\"url\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\",\"name\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"datePublished\":\"2026-06-16T16:07:27+00:00\",\"dateModified\":\"2026-07-16T16:09:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\",\"name\":\"PJWCreative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"caption\":\"PJWCreative\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","og_locale":"zh_CN","og_type":"article","og_title":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals","og_description":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]","og_url":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2026-06-16T16:07:27+00:00","article_modified_time":"2026-07-16T16:09:29+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","type":"image\/jpeg"}],"author":"PJWCreative","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"},"author":{"name":"PJWCreative","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0"},"headline":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer","datePublished":"2026-06-16T16:07:27+00:00","dateModified":"2026-07-16T16:09:29+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"},"wordCount":461,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","url":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","name":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","datePublished":"2026-06-16T16:07:27+00:00","dateModified":"2026-07-16T16:09:29+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer"}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0","name":"PJW\u521b\u610f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","caption":"PJWCreative"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7996"}],"version-history":[{"count":5,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996\/revisions"}],"predecessor-version":[{"id":8001,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996\/revisions\/8001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7606"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7996"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}